Overview
To assess the evaluation of banana flower stamens extract on prevention of benign prostatic hyperplasia in adults
Description
This is a double-blind and randomized study. Subjects are informed to consume the samples every day for 2 months. The clinical diagnosis item of benign prostatic hyperplasia (BPH) is evaluated by the doctor. The questionnaires are collected at every visit of the trial.
Eligibility
Inclusion Criteria:
- Male aged 40-80 years old
- 7 ≤ IPSS score <19
- The subject did not take α-blocker or anticholinergic agents in the last 8 weeks. The subject did not take 5α-reductase inhibitor or androgen suppression agents in the last 16 weeks (depending on medical history).
- The subject isn't diagnosed with cancer
- The subject is able to read and finish the information on the questionnaire.
- The subject must read and sign the informed consent form after the study has been fully explained.
Exclusion criteria:
- The subject has a history of epilepsy or convulsions, liver and kidney disease, cancer, endocrine disease, mental illness, alcohol or drug abuse, and other major organic diseases (depending on medical history).
- The lower urinary tract urination symptoms of the subject are not related to prostatic hypertrophy (depending on medical history).
- Residual urine volume > 250 mL (depending on medical history)
- Subjects have had pelvic radiation therapy or pelvic surgery (including prostate or bladder surgery, but those who only have had a prostate slice can participate in the trial).
- Subjects have taken sexual hormone preparations including LHRH agonists, anti-androgens, feminine, or Penta-reductase inhibitors (Proscar and Avodart) 16 weeks prior to the trial.
- Subjects have participated in other clinical trials 12 weeks prior to the trial.